The use of drugs Laferomaks and Prosteks in treatment of chronic bacterial prostatitis, combined with benign prostatic hyperplasia
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: Studying the efficiency of complex treatment of patients with chronic bacterial prostatitis, combined with prostatic hyperplasia using drugs Laferomaks (interferon alfa-2β, rectal suppositories) and Prosteks (extract of bulls` prostate) produced by «PF «Biopharma».
Patients and methods. 52 patients were treated with a confirmed diagnosis of «CP, combined with initial symptoms of PH». Patients were divided into two groups. The study group included 26 patients during therapy they were designed Laferomaks 3 mln ME in the morning and evening for 10 days, then as a second stage of treatment – the drug Prosteks 0.03 in the morning and evening for 10 days. The control group included 26 patients who received standard treatment without using of drugs Laferomaks and Prosteks.
Results. The survey results confirm the effectiveness of a course of adjuvant therapy, as evidenced by reduction in the number of white blood cells in both groups of patients. Statistically significant results were obtained in patients of the main group for performance evaluation criteria urodynamic examination and reducing the symptoms of a scale IPSS and quality of life.
Conclusion. Alpha-epineblockers and antibiotics are the first line drugs in patients with benign prostatic hyperplasia and chronic prostatitis, but their use in combination with Laferomaks Prosteks and significantly improve the results of their application.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Мавров И.И. Половые болезни: Энциклопедический справочник. – К.: Укр.энцик.; М.: «АСТ-Пресс», 1994. – 480 с.
Возианов С.А, Возианова С.В., Бойко А.И., Мартыненко А.В., Чумак Н.Н., Губарь А.А. Хронический простатит /Под редакцией профессора Возианова С.А. – К.: «Полиграф-UA». – 2017. – 100 с.
Попков В.М., Чураков А.А., Долгов А.Б., Дерюгина Л.А. Роль условно-патогенной микрофлоры при хроническом простатите, ассоциированном с Chlamydia trachomatis // Фундаментальные исследования. – 2014. – No 10–7. – С. 1386–1388.
Мартыненко А.В. Сравнительная клинико-экономическая эффективность фармакологических средств, применяемых при лечении инфекций, передающихся половым путем // Современные инфекции. – 2002. – No 1. – С. 61–64.
Мартыненко А.В. Сравнительная фармакоэкономическая эффективность альфа адреноблокаторов различных фирм производителей при лечении хронического простатита // Врачебное дело. – 2003. – No 1. – С. 99–101.
Имшинецкая Л.П., Сапсай В.И., Сапсай А.В. Мужское бесплодие / Под редакцией профессора И.И. Горпиченко. – К.: «Аврора плюс». – 2005. – 84 с.
